CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with December 17, 2018 AMENDED AND RESTATED SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD HEDGEPATH...Sublicense Agreement • March 7th, 2019 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Maryland
THIS AMENDED AND RESTATED SUBLICENSE AGREEMENT (this “Agreement”) is entered into effective as of December 17, 2018 by and between MAYNE PHARMA INTERNATIONAL PTY LTD, ABN 88 007 870 984, an Australian body corporate having an address at 1538 Main North Road, Salisbury South, SA 5106, Australia (“Mayne Pharma”), and HEDGEPATH PHARMACEUTICALS, INC., a company incorporated in Delaware having an address at 324 South Hyde Park Avenue #350, Tampa, Florida, 33606, United States (“HPPI”) with respect to the following:
AGREEMENTSupply and License Agreement • March 7th, 2019 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665Supply and License Agreement • March 7th, 2019 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • Delaware
A Mayne Pharma International Pty Ltd, a company incorporated in Australia (ACN 007 870 984) (MPI) and HPPI entered into that certain Supply and License Agreement dated on or about September 3, 2013 (the “Original Agreement”).
